Prognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences

Basit Öğe Kaydı
dc.contributor.authorUstaalioglu, Bala Basak Oven
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorTuran, Nedim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKaya, Serap
dc.contributor.authorEren, Tulay
dc.contributor.authorUlas, Arife
dc.date.accessioned2024-04-24T17:28:16Z
dc.date.available2024-04-24T17:28:16Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors related with adjuvant treatment decisions for stage I and IIA NSCLC patients without lymph node metastasis. Materials and Methods: We retrospectively analyzed 302 patients who had undergone curative surgery for prognostic factors regarding survival and clinicopathological factors related to adjuvant chemotherapy. Results: Nearly 90% of the patients underwent lobectomy or pneumonectomy with mediastinal lymph node resection. For the others, wedge resection were performed. The patients were diagnosed as stage IA in 35%, IB in 49% and IIA in 17%. Histopathological type (p=0.02), tumor diameter (p=0.01) and stage (p<0.001) were found to be related to adjuvant chemotherapy decisions, while operation type, lypmhovascular invasion (LVI), grade and the presence of recurrence were important factors in predicting overall survival (OS), and operation type, tumor size greater than 4 cm, T stage, LVI, and visceral pleural invasion were related with disease free survival (DFS). Multivariate analysis showed operation type (p<0.001, hazard ratio (HR):1.91) and the presence of recurrence (p<0.001, HR:0.007) were independent prognostic factors for OS, as well visceral pleural invasion (p=0.01, HR:0.57) and LVI (p=0.004, HR:0.57) for DFS. Conclusions: Although adjuvant chemotherapy is standard for early stage lymph node positive NSCLC, it has less clear importance in stage I and IIA patients without lymph node metastasis.en_US
dc.identifier.doi10.7314/APJCP.2013.14.11.6287
dc.identifier.endpage6292en_US
dc.identifier.issn1513-7368
dc.identifier.issue11en_US
dc.identifier.pmid24377519
dc.identifier.scopus2-s2.0-84892467425
dc.identifier.scopusqualityQ3
dc.identifier.startpage6287en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2013.14.11.6287
dc.identifier.urihttps://hdl.handle.net/11468/20386
dc.identifier.volume14en_US
dc.identifier.wosWOS:000329829200015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectLymph Node Negativeen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectPrognosisen_US
dc.titlePrognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiencesen_US
dc.titlePrognostic Factors for Lymph Node Negative Stage I and IIA Non-small Cell Lung Cancer: Multicenter Experiences
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu